Background The genetic basis of familial hypertrophic cardiomyopathy (HCM) is well described,
but the relation between genotype and clinical phenotype is still poorly characterised. …

Background Clinical interpretation of the large number of rare variants identified by high
throughput sequencing (HTS) technologies is challenging. The aim of this study was to explore …

Background Left ventricular maximum wall thickness (MWT) is central to diagnosis and risk
stratification of hypertrophic cardiomyopathy, but human measurement is prone to variability. …

Aims Myocardial scar detected by cardiovascular magnetic resonance has been associated
with sudden cardiac death in dilated cardiomyopathy (DCM). Certain genetic causes of …

Objective A predictable relation between genotype and disease expression is needed in
order to use genetic testing for clinical decision-making in hypertrophic cardiomyopathy (HCM). …

Background Predictive genetic screening of relatives of patients with hypertrophic cardiomyopathy
(HCM) caused by sarcomere protein (SP) gene mutations is current standard of care, …

Aims The aim of this study was to determine the frequency of heterozygous truncating ALPK3
variants (ALPK3tv) in patients with hypertrophic cardiomyopathy (HCM) and confirm their …

Background— Mutations in genes coding for sarcomeric proteins cause hypertrophic
cardiomyopathy. Subtle abnormalities of the myocardium may be present in mutation carriers …

Background— Sarcomere protein mutations in hypertrophic cardiomyopathy induce subtle
cardiac structural changes before the development of left ventricular hypertrophy (LVH). We …

Background Variants in myosin heavy chain 7 (MYH7) are responsible for disease in 1% to
5% of patients with dilated cardiomyopathy (DCM); however, the clinical characteristics and …